Evolution of SGLT2 Inhibitors in Treatment Regimens
Javed Butler, MD, MPH, MBA, reviews the historical background of using SGLT2 inhibitors and the impact on patients with heart failure with reduced ejection fraction.
Role of MRA Blockers in HF Treatment
Evaluating the facilitation of an MRA (mineralocorticoid receptor antagonist) when using an optimal adjuvant medical therapy for the treatment of heart failure.
Current Protocols in Psychiatric Care
Henry Nasrallah, MD, compares the European Guidelines and United States Guidelines; the panel discusses guidelines currently in place for psychiatric patients.
Lack of Guideline-Supported Protocols
Joe Avelino, RN, BSN, MHSA, CPHQ, defines a hospital versus an institution; and Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the lack of guideline-supported protocols for patients
Role and Impact of Prescription Monitoring Programs
Experts share insights on how they have utilized Prescription Monitoring Programs to combat the opioid crisis and improve the safety of prescribed opioids.
Essential Patient Education Considerations for Naloxone
Experts share approaches to normalize conversations about naloxone with patients, as well as share important considerations for maximizing naloxone education.
Using Systemic Treatment in Atopic Dermatitis
A review of the safety and efficacy of systemic agents such as methotrexate, azathioprine, and cyclosporine in patients with severe, persistent atopic dermatitis.
Role of Nonsteroidal Topical Therapies in AD Management
Experts in the management of atopic dermatitis review the safety and efficacy of topical calcineurin inhibitors and topical PDE4 inhibitors.
Target Dose in HF Therapies for Reduced Ejection Fraction
Contraindications for clinicians to keep in mind when administering sacubitril/valsartan therapy, and an examination of target dose for therapies in heart failure with reduced ejection fraction.
Considering ARNIs as De Novo Therapy in Heart Failure
Considerations for initiating sacubitril/valsartan as de novo therapy in patients naïve to angiotensin-converting enzyme inhibitors or angiotensin receptor blocker therapies as per the 2021 update of the expert consensus decision pathway document.
Understanding When to Start LAIs in Schizophrenia
Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, review how early long-acting injectables should be started in patients with schizophrenia.
Transitioning from Oral to LAIs to Manage Schizophrenia
Henry Nasrallah, MD, and Rahn Bailey, MD, DFAPA, discuss how to switch a patient from oral to a long-acting injectable antipsychotic from their own experience.
Are Recommendations Infringing Upon Practice Autonomy?
Multidisciplinary panel of clinicians discuss whether recommendations made by national, state, and local agencies infringes upon clinical practice autonomy.